Role of ELABELA in prediction and early warning of preeclampsia

Exploring the role of ELABELA in the prediction and early warning of preeclampsia in combination with placental biomarkers and ultrasound: prospective cohort study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100053741

Enrollment

Unknown

Registered

2021-11-28

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia

Interventions

Gold Standard:Clinical outcome

Index test:ELABELA

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Pregnant women whose gestational age is less than 14 weeks after the establishment of the card; 2. Pregnant women who plan to establish a card in our hospital, have regular obstetric examinations and give birth; 3. Pregnant women who voluntarily participated in the survey with informed consent.

Exclusion criteria

Exclusion criteria: Pregnant women who were unable to participate in the survey due to mental illness or physical disability.

Design outcomes

Primary

Measure	Time frame
Peptide small molecule hormone elabela;	—

Countries

China

Contacts

Public ContactLiu Dandan

Chengdu Women's and Children's Central Hospital

17500012@qq.com+86 18981708181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026